Combined treatment of localized prostate cancer with HDR-Iridium 192 remote brachytherapy and external beam irradiation;Die kombinierte behandlung des lokal begrenzten prostatakarzinoms mit HDR-Iridium-192-nachlade-brachytherapie und perkutaner bestrahlung

Strahlentherapie und Onkologie

Volumn 175, Issue 8, 1999, Pages 387-391

  Andreopoulos, Demetrios ^a   Piatkowiak, Michael ^b   Krenkel, Barbara ^b   Schleicher, Ursula Maria ^b   Wolff, Johannes Maria ^b  

^a Bank of Cyprus Group Oncology Centre   (Cyprus)

^b NONE

Author keywords

Brachytherapy; External beam irradiation; Prostate cancer

Indexed keywords

IRIDIUM 192;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; HUMAN; MALE; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 0032812165     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000660050026     Document Type: Article

References (27)

1. Beck-Bornholdt HP. Gewebsspezifische Erholung und ihre Formalisierung für die Bestrahlungsplanung. Das linear-quadratische Modell am Beispiel der Hamburger Ereignisse. In: Bohndorf W, Richter J, Hrsg. Bestrahlungsplanung Aktueller Stand und Perspektiven. Universität Würzburg;1994:72-7.
2. Bice WS, Prestidge BR, Grimm PD. Centralized multiinstitutional post-implant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998;41:921-7.
3. Borghede G, Hedelin H, Holmäng S, et al. Combined treatment with temporary short-term high dose rate Iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 1997;44:237-44.
4. Borghede G, Hedelin H, Holmäng S, et al. Irradiation of localized prost-atic carcinoma with a combination of high dose rate Iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol 1997;44:245-50.
5. D'Amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-defined prostate cancer: the jury is still out. J Clin Oncol 1996;14:304-15.
6. Dinges S, Deger S, Koswig S, et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer - results of a prospective trial. Radiother Oncol 1998;48:197-202.
7. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94.
8. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radial Oncol Biol Phys 1988;15:1299-305.
9. Horwitz EM, Vicini FA, Ziaja EL, et al. An analysis of clinical and treatment related prognostic factors on outcome using biochemical control as an end-point in patients with prostate cancer treated with external beam irradiation. Radiother Oncol 1997;44:223-8.
10. Kovács G, Galalae R. Wirth B, et al. Optimierung der interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom mit einer neuen Implantationstechnik. Strahlenther Onkol 1995;171:685-8.
11. Koväcs G, Wirth B, Bertermann H, et al. Prostate preservation by combined external beam and HDR brachytherapy at nodal negative prostate cancer patients - an intermediate analysis after ten years experience. Int J Radiat Oncol Biol Phys 1996;36:Suppl:198.
12. Lawton CA, Won M, Pilepich MV. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991;21: 935-9.
13. Malcolm AB, Kaplan ID, Cox RC. Radiation therapy for localized disease. Cancer 1993;71:939-52.
14. Mate TP, Gottesman JE, Hatton J, et al. High dose-rate afterloading 192 iridium prostate brachytherpy: feasibility report. Int J Radiat Oncol Biol Phys 1998;41:525-33.
15. Middleton RG, Thompson IM, Austenfeld MS. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol 1995;154:2144-8.
16. Paul R, Hofmann R, Schwarzer JU, et al. Iridium 192 high-dose-rate brachytherapy - a useful alternative therapy for localized prostate cancer? World J Urol 997;15:252-6.
17. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990; 144:1180-4.
18. Porter AD, Forman JD. Prostate brachytherapy - an overview. Cancer 1993;71:953-8.
19. Prestidge BR, Prete JJ, Buchholz TA. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radial Oncol Biol Phys 1998;40:461-5.
20. Sack H. Prostata Karzinom. In: Scherer E. Sack H, Hrsg. Strahlentherapie, 4. Aufl. Berlin-Heidelberg-New York: Springer, 1996:551-65.
21. Sack H, Nosbuesch H, Stuetzer H. Radiotherapy of prostate carcinoma: results of treatment and complications. Radiother Oncol 1987;10:7-15.
22. Schwarzer JU, Hofmann R, Kneschaurek P, et al. High-dose-rate-Brachytherapie des Prostatakarzinoms mit Iridium-192. Strahlenther Onkol 1992;168:17-22.
23. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993;150:1856-9.
24. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998;41:101-8.
25. Wiegel T, Höller U, Wiegel K, et al. High-dose-rate 192 Iridium afterloading therapy followed by percutaneous irradiation for prostate cancer -results of a prospective clinical trial. In: Richter E, Feyerabend T, Marx M, Hrsg. Deutsche Brachytherapie Konferenz '97 Lübeck. Lübeck 1997: 183-93.
26. Wiegel T, Steiner U, Hinkelbein W. Strahlentherapie nach radikaler Prostatektomie. Strahlenther Onkol 1997;173:309-15.
27. Zagars GK, von Eschenbach AC, Ayala AG, et al. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 1991;68:2370-7.